Inventa Trials
Renewed Hope. For 25 years, Fort Wayne Medical Oncology and Hematology has been participating in clinical trials, giving patients renewed hope. We opened the Inventa Center for Cancer Research in order to continue our tradition of leading advanced research and clinical trials. Together, we’re working toward breakthroughs in cancer treatment through partnerships with top academic research programs across the country. However, as our patient, you don’t have to travel to take advantage of these opportunities. You can receive these cutting-edge treatment options here at home.
While not everyone is a candidate for clinical trials, there are many trials available to those who qualify. Click on the links below to learn. Of course our physicians will always take the time to discuss treatment options, including clinical trials, to determine the right plan of action for you.
| Trial No. | Trial Name |
|---|---|
| BMS
CA209-274 |
A Phase 3 Randomized, Double-Blind, Multi-Center Study of Adjuvant Nivolumab Versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma |
| ER+/HER- | |
| Takeda
C31006 |
An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2 Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy |
| Triple Negative | |
| Cascadian
ONT-380-206 HER2CLIMB |
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capectiabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma |
| Syndax
SNDX-275-0602 (TRIO-025) |
A Randomized , Placebo-Controlled, Double-Blind, Multicenter Phase 2 Study of Atezolizumab with or without Entinostat in Patients with Advanced Triple Negative Breast Cancer, with a Phase 1b Lead in Phase |
| Trial No. | Trial Name |
|---|---|
| Alexion
ALXN1210-aHUS-311 |
Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome |
| Trial No. | Trial Name |
|---|---|
| AML | |
| ABBVIE
M15-656 |
A Randomized, Double-Blind, Placebo Controlled Study of Venetoclax in Combination with Azacitidine
Versus Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia Who are Ineligible
for Standard Induction Therapy
*Special Note - Patients Must be Able to Receive Treatment at Lutheran Hospital |
| Trial No. | Trial Name |
|---|---|
| SCLC | |
| AstraZeneca
D419QC00001 Caspian |
A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination with Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease On Hold Pending Availablilty of Etopside |
| NSCLC | |
| BMS
CA209-384 |
A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240mg Every 2 Weeks vs Nivolumab 480mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3mg/kg or 240 mg Every 2 Weeks |
| Trial No. | Trial Name |
|---|---|
| TG Therapeutics
UTX-TGR-205 |
A Phase 2b Randomized Study of Ublituximab + TGR-1202 +/- Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma |
| Trial No. | Trial Name |
|---|---|
| AstraZeneca
D8488C00001 Concerto |
A Single Arm, Open-Label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women with Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer Who Do Not Carry a Deleterious or Suspected Deleterious Germline BRCA Mutation |
| Trial No. | Trial Name |
|---|---|
| ARMO
AM0010-301 ARTIST 1 |
A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer that Have Progressed During or Following a First-Line Gemcitabine Containing Regimen |
| Halozyme
HALO-109-301 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluranan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma |
| Trial No. | Trial Name |
|---|---|
| SCRI
GU115 |
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide with or without the P13 Kinase/MTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer |
| Trial No. | Trial Name |
|---|---|
| Medivation
3800-01 |
A Phase 1 Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) in Patients with Advanced Solid Tumors and Normal or Varying degrees of Renal impairment. *Only open to Group D Severe Renal Impairment |
| BMS
CA209-627 "Basket" |
An Open-label Phase 2 Multi-Cohort Trial of Nivolumab in Advanced or Metastatic Malignancies. |